A detailed history of China Universal Asset Management Co., Ltd. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 21,466 shares of PCVX stock, worth $1.94 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
21,466
Previous 12,781 67.95%
Holding current value
$1.94 Million
Previous $965,000 153.89%
% of portfolio
0.27%
Previous 0.14%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$70.52 - $117.12 $612,466 - $1.02 Million
8,685 Added 67.95%
21,466 $2.45 Million
Q2 2024

Jul 19, 2024

SELL
$60.06 - $78.77 $484,023 - $634,807
-8,059 Reduced 38.67%
12,781 $965,000
Q1 2024

Apr 29, 2024

SELL
$59.79 - $81.05 $1.28 Million - $1.73 Million
-21,327 Reduced 50.58%
20,840 $1.42 Million
Q4 2023

May 21, 2024

BUY
$45.35 - $63.41 $967,179 - $1.35 Million
21,327 Added 102.34%
42,167 $2.65 Million
Q4 2023

Jan 23, 2024

SELL
$45.35 - $63.41 $11,020 - $15,408
-243 Reduced 0.57%
42,167 $2.65 Million
Q3 2023

May 21, 2024

BUY
$46.0 - $53.1 $54,372 - $62,764
1,182 Added 2.87%
42,410 $2.16 Million
Q3 2023

Oct 30, 2023

BUY
$46.0 - $53.1 $54,372 - $62,764
1,182 Added 2.87%
42,410 $2.16 Million
Q2 2023

May 21, 2024

BUY
$34.66 - $54.07 $1.39 Million - $2.17 Million
40,144 Added 3703.32%
41,228 $2.06 Million
Q2 2023

Jul 27, 2023

BUY
$34.66 - $54.07 $1.39 Million - $2.17 Million
40,144 Added 3703.32%
41,228 $2.06 Million
Q1 2023

May 21, 2024

BUY
$36.27 - $47.2 $10,191 - $13,263
281 Added 34.99%
1,084 $40,000
Q1 2023

Apr 27, 2023

BUY
$36.27 - $47.2 $10,191 - $13,263
281 Added 34.99%
1,084 $41,000
Q4 2022

May 21, 2024

SELL
$20.58 - $47.95 $412,361 - $960,774
-20,037 Reduced 96.15%
803 $38,000
Q4 2022

Jan 31, 2023

BUY
$20.58 - $47.95 $5,103 - $11,891
248 Added 44.68%
803 $39,000
Q3 2022

Oct 21, 2022

BUY
$21.69 - $28.53 $12,037 - $15,834
555 New
555 $13,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.36B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.